Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Next Previous
X
Search
Trial Profile

A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ultevursen (Primary)
  • Indications Deaf blind disorders; Retinitis pigmentosa; Usher syndromes
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms STELLAR
  • Sponsors ProQR Therapeutics

    • Most Recent Events

    • 19 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 18 Nov 2021 According to a ProQR Therapeutics media release, the company present data of this study at the Analyst Event via webcast.
    • 04 Nov 2021 According to a ProQR Therapeutics media release, in Sep 2021, findings from this study will be presented at the European Society of Retina Specialists (EURETINA) virtual congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top